$GEHC

Lobo Kevin purchased $642K of GEHC

Lobo Kevin purchased 10,000 shares of GE HealthCare Technologies Inc. (GEHC) at $64.18 ($0.64M total) on 2026-05-22.

Original reporting
SEC EDGAR · Lobo Kevin
Published May 26, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GEHC
Bullish
medium confidence
Mentioned
$GEHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The market may interpret the purchase as a positive signal, but without earnings, guidance, or deal details the effect is likely sentiment-driven rather than thesis-changing.

02

Market read

A director’s open-market buy in GEHC may provide a small sentiment tailwind, but it is not a standalone fundamental catalyst.

03

What to watch

Check for follow-on insider transactions, volume/price reaction around 2026-05-22, and whether other insiders simultaneously bought/sold.

Relevance 7/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-26, covering trade on 2026-05-22).

Background

This is an SEC Form 4 insider transaction disclosure (director open-market purchase) for GE HealthCare Technologies.

Company-level read

Ticker impact

$GEHCBullishMedium confidence
Context

GE HealthCare director Lobo Kevin filed an open-market purchase of 10,000 shares at $64.18 on 2026-05-22.

Expected impact

Likely limited near-term impact; any move may fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a director open-market purchase with no 10b5-1 plan and a disclosed post-trade holding, but no new operating information is provided.

Market effects

Minimal; insider activity in one medtech/healthcare name typically does not reset sector expectations without accompanying company-specific news.

None indicated; disclosure is US-listed and does not reference regional operations.

Low; no international deal/regulatory development mentioned.

Counterpoint

Open-market insider buys can be routine (tax/portfolio rebalancing) and may not reflect a new view on near-term fundamentals.

Key entities

  • GE HealthCare Technologies Inc.

    Filed SEC Form 4 showing director Lobo Kevin purchased 10,000 shares on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GEHCHighAI 9/10

GE HealthCare Surges on Q3 Beat and Raised Outlook

GE HealthCare (GEHC) shares rose 5.4% in pre-market trading after Q3 2026 earnings beat estimates, with adjusted EPS of $1.34 vs. $1.20 consensus and revenue of $5.5B vs. $5.35B. The company raised full-year EPS guidance to $4.95–$5.05. CEO Peter Arduini cited strong growth and margin expansion. Free cash flow increased to $793M, up $310M year-over-year.

$GEHCHighAI 9/10

Why is GE HealthCare stock surging today?

GE HealthCare (GEHC) stock rose 5.4% in pre-market trading after its Q3 2026 results exceeded expectations, with adjusted EPS of $1.34 vs. $1.20 expected, and revenue of $5.5B vs. $5.35B. The company raised its full-year guidance, citing strong growth and margin expansion. Short interest at 18.5M shares amplified the upside move. CEO Peter Arduini highlighted growth across all segments and noted no structural barriers in China.

$GEHCMedAI 8/10

GE HealthCare Q3 Revenue Rises 7.2% to $5.5 Billion

GE HealthCare reported Q3 2026 revenue of $5.5B, up 7.2% YoY. Organic revenue and orders grew 6.2% and 4%, respectively. Net income rose to $615M from $446M, with margins improving. The company raised its full-year 2026 guidance, citing strong performance and momentum.

$GEHCHighAI 9/10

GE HealthCare’s (NASDAQ:GEHC) Q3 2026 sales beat estimates

GE HealthCare reported Q3 2026 revenue of $5.51B, exceeding estimates by 3% and growing 7.2% YoY. Adjusted EPS was $1.34, beating estimates by 11.3%. The company raised its full-year adjusted EPS guidance to $5 at the midpoint. Operating and free cash flow margins improved to 14.6% and 14.4%, respectively, up from the prior year.